Expression and amplification of eIF-5A2 in human epithelial ovarian tumors and overexpression of EIF-5A2 is a new independent predictor of outcome in patients with ovarian carcinoma.
about
eIF5A isoforms and cancer: two brothers for two functions?Overexpression of eukaryotic initiation factor 5A2 enhances cell motility and promotes tumor metastasis in hepatocellular carcinoma.Overexpression of eIF5A-2 is an adverse prognostic marker of survival in stage I non-small cell lung cancer patients.Expression of eukaryotic initiation factor 5A and hypusine forming enzymes in glioblastoma patient samples: implications for new targeted therapiesCisplatin sensitivity is enhanced in non-small cell lung cancer cells by regulating epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2.Overexpression of eukaryotic translation initiation factor 5A2 (EIF5A2) correlates with cell aggressiveness and poor survival in gastric cancerBiological Relevance and Therapeutic Potential of the Hypusine Modification System.MiR-30b suppresses tumor migration and invasion by targeting EIF5A2 in gastric cancerLentivirus-mediated shRNA interference of clusterin blocks proliferation, motility, invasion and cell cycle in the ovarian cancer cells.Identification of recurrent focal copy number variations and their putative targeted driver genes in ovarian cancerThe translation factor eIF5A and human cancer.Eukaryotic translation initiation factor 5A2 regulates the migration and invasion of hepatocellular carcinoma cells via pathways involving reactive oxygen species.Identification and validation of AIB1 and EIF5A2 for noninvasive detection of bladder cancer in urine samplesRole of Eukaryotic Initiation Factors during Cellular Stress and Cancer ProgressionEukaryotic translation initiation factor 3 subunit D overexpression is associated with the occurrence and development of ovarian cancerEIF5A2 predicts outcome in localised invasive bladder cancer and promotes bladder cancer cell aggressiveness in vitro and in vivo.MicroRNA-9 regulates non-small cell lung cancer cell invasion and migration by targeting eukaryotic translation initiation factor 5A2.Roles of eukaryotic initiation factor 5A2 in human cancer.The proteome under translational control.Overexpression of CK20, MAP3K8 and EIF5A correlates with poor prognosis in early-onset colorectal cancer patients.Expression of eukaryotic translation initiation factor 5A-2 (eIF5A-2) associated with poor survival in gastric cancer.Targeting the polyamine-hypusine circuit for the prevention and treatment of cancer.EIF5A2 is a novel chemoresistance gene in breast cancer.Role of EIF5A2, a downstream target of Akt, in promoting melanoma cell invasion.Down-regulation of eIF5A-2 prevents epithelial-mesenchymal transition in non-small-cell lung cancer cells.Eukaryotic translation initiation factors and cancer.Blocking Modification of Eukaryotic Initiation 5A2 Antagonizes Cervical Carcinoma via Inhibition of RhoA/ROCK Signal Transduction Pathway.N1-guanyl-1, 7-diaminoheptane enhances the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine via the inhibition of eukaryotic translation initiation factor 5A2.Eukaryotic translation initiation factor 5A2 (eIF5A2) regulates chemoresistance in colorectal cancer through epithelial mesenchymal transition.Prognostic significance of the expression of nuclear eukaryotic translation initiation factor 5A2 in human melanoma.Separation of low and high grade colon and rectum carcinoma by eukaryotic translation initiation factors 1, 5 and 6.Eukaryotic Initiation Factor 5A2 Contributes to the Maintenance of CD133(+) Hepatocellular Carcinoma Cells via the c-Myc/microRNA-29b Axis.Overexpression of eukaryotic initiation factor 5A2 (EIF5A2) is associated with cancer progression and poor prognosis in patients with early-stage cervical cancer.MicroRNA-9 enhances sensitivity to cetuximab in epithelial phenotype hepatocellular carcinoma cells through regulation of the eukaryotic translation initiation factor 5A-2.Eukaryotic translation initiation factor 5A2 promotes metabolic reprogramming in hepatocellular carcinoma cells.
P2860
Q26830163-586E3D40-F7D6-4EF9-AFF0-786C52E2A662Q34095605-0077EAC2-A9C5-4F09-8229-1FD0C20C6129Q34137202-BAC82FD4-7025-4D3B-A990-046BF6FF42CAQ34395707-DC72AA32-5036-44AE-A42C-43F4499A6C24Q34515582-981D810F-5D46-408A-8D75-8CD6DB894893Q35202594-3FABE223-A9C0-435C-8D6B-F957E8A2E24BQ35883784-87412914-376E-4D0F-A7A1-7638BB1274A2Q35970141-FD5A73D5-0E81-4EF9-955E-D70FBC73077AQ35986590-7E48FA75-7BC0-4CD2-B9BB-AC85F9B3D9B4Q36031493-EB39D2AF-71C5-4A83-AF2C-144704F0AA22Q36519353-58A80A93-6B1C-4E9D-A6FC-A2C29858E048Q37269303-66099596-82DB-4E83-9752-089728F7DEE6Q37520334-EAAE090D-C10D-4B3F-A48A-D04A4355B195Q37548069-3A00679B-F57A-4186-920F-3A45EDDBA24AQ37635646-97F1C486-E5C8-490A-A30B-BD116307AB7CQ37681730-4665231B-321E-4004-BDD3-C217CC246C80Q37685242-89A3FEA0-EE66-4548-A093-6DC0147890DFQ38163977-C6AB133F-1113-4527-ABDB-9F3B7A26E510Q38255027-51431DE5-2E55-4CF9-B834-34BEC8A9932FQ38318476-989A2492-EADB-4F6B-8B5C-3B12DA04601AQ38843125-C5D47B60-F286-4C3A-A965-3F437EDA5379Q38881007-8D59B878-0DA6-4B65-8FF4-AE083A9E8B72Q39014521-62DE9A89-09AA-4546-BEC0-AC62596FCEE7Q39068047-FFECD533-844C-43EE-914A-3E44036451FCQ39144255-79947DFB-FB7C-47C6-9A04-53EA07DCE05AQ39400409-4AAA1CCC-C303-4A1B-88A4-22D22630127DQ39408668-06663E36-DB05-4BE6-A138-0D2E8FE9E9E9Q41672712-ABE7F2D2-B4A1-4357-8FB4-9CE20ABAC341Q41789947-A696FFAF-5329-41A7-B62B-930B613D7E92Q42031208-C47DC712-0043-4E3E-A44B-D104A8505608Q47280262-D96B1CEA-C5C3-49FF-B582-5CFA2C12F498Q47422423-40EB1C8A-AD8A-492B-8A20-3CE0CF1DAA58Q48879179-B9008998-67D7-4710-86EC-D6E80F0C8B10Q49335206-7499DA76-EF84-4F2E-996F-21059D90ABE1Q51049728-9A87B8FD-D054-4AFB-8AE6-48C29E1EE2FB
P2860
Expression and amplification of eIF-5A2 in human epithelial ovarian tumors and overexpression of EIF-5A2 is a new independent predictor of outcome in patients with ovarian carcinoma.
description
2008 nî lūn-bûn
@nan
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Expression and amplification o ...... tients with ovarian carcinoma.
@ast
Expression and amplification o ...... tients with ovarian carcinoma.
@en
Expression and amplification o ...... tients with ovarian carcinoma.
@nl
type
label
Expression and amplification o ...... tients with ovarian carcinoma.
@ast
Expression and amplification o ...... tients with ovarian carcinoma.
@en
Expression and amplification o ...... tients with ovarian carcinoma.
@nl
prefLabel
Expression and amplification o ...... tients with ovarian carcinoma.
@ast
Expression and amplification o ...... tients with ovarian carcinoma.
@en
Expression and amplification o ...... tients with ovarian carcinoma.
@nl
P2093
P1433
P1476
Expression and amplification o ...... atients with ovarian carcinoma
@en
P2093
Guo-Fen Yang
Hong-Mei Wu
Hsiang-Fu Kung
Ji-Hong Liu
Jun-Hang Luo
Li-Juan Li
Wen-Feng Hua
Yi-Xin Zeng
P304
P356
10.1016/J.YGYNO.2008.10.024
P407
P577
2008-12-02T00:00:00Z